📰 Celcuity Inc View News
Celcuity Inc View News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Celcuity Inc View. Real-time updates on events, politics, business and more.
May 12, 2023
Median progression free survival (PFS) was 48.6 months in treatment-naïve patients with HR+/HER2- advanced breast cancer who were treated with gedatolisib in combination with palbociclib and letrozoleMedian
April 18, 2023
Gedatolisib demonstrated superior anti-proliferative potency and efficacy in endometrial, ovarian and cervical cancer cell lines compared to other PAM inhibitors evaluated regardless of PTEN, P13K, or
April 12, 2023
MINNEAPOLIS, MN / ACCESSWIRE / April 12, 2023 / Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company focused on development of targeted therapies for oncology, today announced its participation
March 23, 2023
Dosing of first patient in VIKTORIA-1 in the fourth quarter triggered closing of $100 million PIPE financing and drawdown of $20 million term loan tranche, which extends cash runway through 2025Updated
March 16, 2023
MINNEAPOLIS, MN / ACCESSWIRE / March 15, 2023 / Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company focused on development of targeted therapies for oncology, today announced publication
March 16, 2023
MINNEAPOLIS, MN / ACCESSWIRE / March 16, 2023 / Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company focused on development of targeted therapies for oncology, today announced that it will
December 9, 2022
High response rates and encouraging median progression free survival rates were observed in patients regardless of PIK3CA mutation statusMedian progression free survival (PFS) of 42.3 months was reported
December 7, 2022
First patient dosing enables closing of $100 million PIPE financing and drawdown of $20 million term loan trancheMINNEAPOLIS, MN / ACCESSWIRE / December 7, 2022 / Celcuity Inc. (Nasdaq:CELC), a clinical-stage
November 22, 2022
MINNEAPOLIS, MN / ACCESSWIRE / November 22, 2022 / Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company focused on development of targeted therapies for cancer treatment, today announced